4Sc AG banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
Germany DE
Employees
14
IPO date
Feb 25, 2008

4SC AG is a clinical-stage biopharmaceutical company, which engages in the development of small molecule drugs that target key indications in cancer. The company is headquartered in Planegg, Bayern and currently employs 14 full-time employees. The company went IPO on 2008-02-25. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.

4Sc AG Investor Relations

Address
Fraunhoferstr. 22, Martinsried
Planegg, Bayern
Germany

Management

Dr. Jason Loveridge B.Sc., B.Sc, Ph.D., FRSM

Chairman of Management Board, CEO & MD

Biography unavailable

Ms. Anna Niedl Ph.D.

Corp. Communications & Investor Relations Officer

Biography unavailable

Dr. Susanne Danhauser-Riedl M.D.

Chief Medical Officer

Biography unavailable

Dr. Frank Hermann M.D.

Chief Devel. Officer

Biography unavailable

Ms. Larissa Stuttem

Team Assistant

Biography unavailable

1 / 5